Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for ≥ 156 Consecutive Weeks : A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial
-
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau)
;
Costanzo, Antonio (Humanitas Clinical and Research Center IRCCS) ;
de Jong, Elke M. G. J. (Radboud University Medical Center) ;
Torres, Tiago (University of Porto) ;
Warren, Richard B. (The University of Manchester) ;
Wapenaar, Robert (Janssen-Cilag BV (Breda, Països Baixos)) ;
Wegner, Sven (Janssen-Cilag GmbH (Neuss, Alemanya)) ;
Gorecki, Patricia (Janssen-Cilag Ltd (High Wycombe, Regne Unit)) ;
Gramiccia, Talia (Janssen-Cilag SpA (Milà, Itàlia)) ;
Jazra, Maria (Janssen-Cilag (París, França)) ;
Buyze, Jozefien (Janssen Pharmaceutica NV (Beerse, Bèlgica)) ;
Conrad, Curdin (University of Lausanne) ;
Universitat Autònoma de Barcelona
visitante ::
identificación
Subscribirse to this discussion. You will then receive all new comments by email.
